Antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from a Phase 2 clinical trial of ridinilazole (SMT19969) and vancomycin

OBJECTIVES: We evaluated the antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from participants in a Phase 2 study of ridinilazole, a novel targeted-spectrum agent for treatment of C. difficile infection. METHODS: Participants received ridinilazole (200 mg twice daily) or...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Antimicrob Chemother
Main Authors: Snydman, David R, McDermott, Laura A, Thorpe, Cheleste M, Chang, Justin, Wick, Jenna, Walk, Seth T, Vickers, Richard J
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6054158/
https://ncbi.nlm.nih.gov/pubmed/29718329
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dky135
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados